Free Trial

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
BioVie Inc. stock logo
BIVI
BioVie
$8.99
+11.7%
$9.96
$6.20
$75.00
$16.73M0.73188,434 shs53,182 shs
Ensysce Biosciences, Inc. stock logo
ENSC
Ensysce Biosciences
$2.13
-1.4%
$2.21
$1.62
$14.67
$5.05M0.98955,109 shs76,623 shs
Mannatech, Incorporated stock logo
MTEX
Mannatech
$7.83
-2.2%
$9.53
$7.00
$16.49
$14.94M0.896,256 shs32,524 shs
Q32 Bio Inc. stock logo
QTTB
Q32 Bio
$2.19
-5.6%
$1.77
$1.35
$53.79
$26.78M-0.07491,548 shs609,599 shs
5G Stocks: The Path Forward is Profitable Cover

Enter your email address and we'll send you MarketBeat's guide to investing in 5G and which 5G stocks show the most promise.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
BioVie Inc. stock logo
BIVI
BioVie
0.00%+25.91%-17.52%+6.92%+100.67%
Ensysce Biosciences, Inc. stock logo
ENSC
Ensysce Biosciences
0.00%-1.39%0.00%+21.02%-69.66%
Mannatech, Incorporated stock logo
MTEX
Mannatech
0.00%-7.88%-9.58%-20.47%+11.86%
Q32 Bio Inc. stock logo
QTTB
Q32 Bio
0.00%-17.67%+37.30%+3.30%-91.96%
CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & Valuation
BioVie Inc. stock logo
BIVI
BioVie
0.3776 of 5 stars
0.04.00.00.00.60.00.6
Ensysce Biosciences, Inc. stock logo
ENSC
Ensysce Biosciences
0.4622 of 5 stars
0.04.00.00.00.90.00.6
Mannatech, Incorporated stock logo
MTEX
Mannatech
N/AN/AN/AN/AN/AN/AN/AN/A
Q32 Bio Inc. stock logo
QTTB
Q32 Bio
2.1668 of 5 stars
3.14.00.00.00.61.70.6
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
BioVie Inc. stock logo
BIVI
BioVie
4.00
Strong BuyN/AN/A
Ensysce Biosciences, Inc. stock logo
ENSC
Ensysce Biosciences
0.00
N/AN/AN/A
Mannatech, Incorporated stock logo
MTEX
Mannatech
0.00
N/AN/AN/A
Q32 Bio Inc. stock logo
QTTB
Q32 Bio
2.25
Hold$12.17455.56% Upside

Current Analyst Ratings Breakdown

CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
BioVie Inc. stock logo
BIVI
BioVie
N/AN/AN/AN/A$25.35 per shareN/A
Ensysce Biosciences, Inc. stock logo
ENSC
Ensysce Biosciences
$5.21M0.97N/AN/A$2.59 per share0.82
Mannatech, Incorporated stock logo
MTEX
Mannatech
$117.87M0.13$2.13 per share3.68$4.57 per share1.71
Q32 Bio Inc. stock logo
QTTB
Q32 Bio
N/AN/AN/AN/A$0.47 per shareN/A
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
BioVie Inc. stock logo
BIVI
BioVie
-$32.12M-$79.10N/AN/AN/A-100.88%-78.49%8/21/2025 (Estimated)
Ensysce Biosciences, Inc. stock logo
ENSC
Ensysce Biosciences
-$7.99M-$6.54N/AN/AN/A-109.49%-192.54%-121.77%8/13/2025 (Estimated)
Mannatech, Incorporated stock logo
MTEX
Mannatech
$2.49M-$0.10N/AN/A-0.19%-2.56%-0.57%8/12/2025 (Estimated)
Q32 Bio Inc. stock logo
QTTB
Q32 Bio
-$47.73M-$4.94N/AN/AN/AN/A-447.33%-59.77%8/6/2025 (Estimated)

Latest ENSC, BIVI, QTTB, and MTEX Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
8/14/2025Q2 2025
Q32 Bio Inc. stock logo
QTTB
Q32 Bio
-$1.14N/AN/AN/AN/AN/A
8/13/2025Q2 2025
Ensysce Biosciences, Inc. stock logo
ENSC
Ensysce Biosciences
-$1.02N/AN/AN/A$0.67 millionN/A
5/13/2025Q1 2025
Ensysce Biosciences, Inc. stock logo
ENSC
Ensysce Biosciences
-$3.02-$1.39+$1.63-$1.39$0.65 million$1.32 million
5/13/2025Q1 2025
Mannatech, Incorporated stock logo
MTEX
Mannatech
N/A-$0.80N/A-$0.80N/A$26.56 million
5/12/2025Q3 2025
BioVie Inc. stock logo
BIVI
BioVie
-$3.20-$1.50+$1.70-$0.15N/AN/A
5/8/2025Q1 2025
Q32 Bio Inc. stock logo
QTTB
Q32 Bio
-$1.23-$0.90+$0.33-$0.90N/AN/A
CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
BioVie Inc. stock logo
BIVI
BioVie
N/AN/AN/AN/AN/A
Ensysce Biosciences, Inc. stock logo
ENSC
Ensysce Biosciences
N/AN/AN/AN/AN/A
Mannatech, Incorporated stock logo
MTEX
Mannatech
N/AN/AN/AN/AN/A
Q32 Bio Inc. stock logo
QTTB
Q32 Bio
N/AN/AN/AN/AN/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
BioVie Inc. stock logo
BIVI
BioVie
N/A
9.31
9.31
Ensysce Biosciences, Inc. stock logo
ENSC
Ensysce Biosciences
N/A
2.50
2.50
Mannatech, Incorporated stock logo
MTEX
Mannatech
0.46
1.18
0.65
Q32 Bio Inc. stock logo
QTTB
Q32 Bio
1.68
4.71
4.71

Institutional Ownership

CompanyInstitutional Ownership
BioVie Inc. stock logo
BIVI
BioVie
4.59%
Ensysce Biosciences, Inc. stock logo
ENSC
Ensysce Biosciences
5.63%
Mannatech, Incorporated stock logo
MTEX
Mannatech
12.98%
Q32 Bio Inc. stock logo
QTTB
Q32 Bio
31.32%

Insider Ownership

CompanyInsider Ownership
BioVie Inc. stock logo
BIVI
BioVie
2.39%
Ensysce Biosciences, Inc. stock logo
ENSC
Ensysce Biosciences
7.90%
Mannatech, Incorporated stock logo
MTEX
Mannatech
41.50%
Q32 Bio Inc. stock logo
QTTB
Q32 Bio
40.00%
CompanyEmployeesShares OutstandingFree FloatOptionable
BioVie Inc. stock logo
BIVI
BioVie
101.86 million1.82 millionNo Data
Ensysce Biosciences, Inc. stock logo
ENSC
Ensysce Biosciences
102.37 million2.18 millionNot Optionable
Mannatech, Incorporated stock logo
MTEX
Mannatech
2501.90 million1.11 millionNot Optionable
Q32 Bio Inc. stock logo
QTTB
Q32 Bio
3912.20 million7.32 millionN/A

Recent News About These Companies

Leerink Partners Sticks to Its Hold Rating for Q32 Bio (QTTB)
Q32 Bio price target lowered to $15 from $16 at Wells Fargo
Q32 Bio: Q4 Earnings Snapshot
Q32 Bio presents results from SIGNAL-AA Part 2a trial of bempikibart
Piper Sandler Downgrades Q32 Bio (QTTB)
BMO Capital Downgrades Q32 Bio (QTTB)

New MarketBeat Followers Over Time

Media Sentiment Over Time

BioVie stock logo

BioVie NASDAQ:BIVI

$8.99 +0.94 (+11.68%)
Closing price 07/18/2025 03:59 PM Eastern
Extended Trading
$8.52 -0.47 (-5.17%)
As of 07/18/2025 07:59 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

BioVie Inc., a clinical stage biopharmaceutical company, engages in the discovery, development, and commercialization of drugs for the treatment of chronic debilitating conditions in the United States. Its products pipeline includes BIV201, which completed Phase IIa clinical trial for the treatment of ascites caused due to chronic liver cirrhosis; and NE3107, a potentially selective inhibitor of inflammatory extracellular single-regulated kinase, which is in Phase III clinical trial for the treatment of patients with mild to moderate Alzheimer's disease, as well as Phase 2 clinical trial for the treatment of Parkinson's disease. The company was formerly known as NanoAntibiotics, Inc. and changed its name to BioVie Inc. in July 2016. BioVie Inc. was incorporated in 2013 and is headquartered in Carson City, Nevada.

Ensysce Biosciences stock logo

Ensysce Biosciences NASDAQ:ENSC

$2.13 -0.03 (-1.39%)
Closing price 07/18/2025 04:00 PM Eastern
Extended Trading
$2.12 -0.01 (-0.47%)
As of 07/18/2025 07:50 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Ensysce Biosciences, Inc., a clinical-stage pharmaceutical company, engages in developing various prescription drugs for severe pain relief in opioid misuse, abuse, and overdose in the United States. It develops products using Trypsin Activated Abuse Protection (TAAP) platform, an abuse-resistant opioid prodrug technology; and Multi-Pill Abuse Resistance (MPAR) platform, an over-dose protection opioid prodrug technology. The company is developing PF614, a TAAP oxycodone prodrug candidate for the treatment of acute or chronic pain; and PF614-MPAR, a combination product of PF614 and nafamostat for overdose protection against excessive oral ingestion, as well as an oral and inhalation drug product of nafamostat for use against coronaviral infections and other pulmonary diseases, such as cystic fibrosis. It is also developing PF614, an extended-release oxycodone-derivative that releases clinically effective oxycodone; PF329 for pain with abuse protection; PF8001 and PF8026 are extended and immediate-release prodrugs of amphetamine for ADHD; and PF9001 to treat Opioid use disorder. The company was founded in 2003 and is based in La Jolla, California.

Mannatech stock logo

Mannatech NASDAQ:MTEX

$7.83 -0.18 (-2.25%)
Closing price 07/18/2025 03:58 PM Eastern
Extended Trading
$7.88 +0.04 (+0.57%)
As of 07/18/2025 04:04 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Mannatech, Incorporated operates as a health and wellness company in the Americas, Europe, the Middle East, Africa, and the Asia-Pacific. The company develops, markets, and sells nutritional supplements; topical and skin care, and anti-aging products; and weight-management and fitness products. It primarily sells its products directly, as well as through e-commerce and network marketing channels. Mannatech, Incorporated was incorporated in 1993 and is headquartered in Flower Mound, Texas.

Q32 Bio stock logo

Q32 Bio NASDAQ:QTTB

$2.19 -0.13 (-5.60%)
Closing price 07/18/2025 04:00 PM Eastern
Extended Trading
$2.21 +0.02 (+0.96%)
As of 07/18/2025 07:57 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Q32 Bio Inc., a clinical-stage biotechnology company, develops biologic therapeutics to restore healthy immune balance in patients with autoimmune and inflammatory diseases driven by pathological immune dysfunction in the United States. Its lead product candidate is ADX-097, a humanized anti-C3d monoclonal antibody fusion protein to restore complement regulation, which has completed Phase I clinical trial for the treatment of renal and other complement-mediated diseases of high unmet need, including lupus nephritis, immunoglobulin A nephropathy, complement component 3 glomerulopathy, and anti-neutrophil cytoplasmic antibody-associated vasculitis. The company is also developing Bempikibart (ADX-914), a fully human antiinterleukin-7 receptor alpha antagonist monoclonal antibody designed to re-regulate adaptive immune function by blocking signaling mediated by interleukin-7 and thymic stromal lymphopoietin that is Phase II clinical trial for the treatment of atopic dermatitis and alopecia areata. Q32 Bio Inc. was formerly known as AdMIRx Inc. and changed its name to Q32 Bio Inc. in April 2020. The company was founded in 2017 and is based in Waltham, Massachusetts.